Amgen seeking partner to develop ex-Synergen pipeline of anti-inflammatory drugs.
Executive Summary
AMGEN SEEKING CORPORATE PARTNER TO DEVELOP EX-SYNERGEN PIPELINE, which includes three products that have remained stagnant in the development stage since Amgen acquired the biotech firm in 1994. Amgen said that by seeking a partner, it will "ensure that the full potential of its inflammation program is realized."